Engineering novel binding proteins from nonimmunoglobulin domains

1. Engineering novel binding proteins from nonimmunoglobulin domains 생화학특론 발표일자 : 2010.3.17 발표자 : 한원석 지도교수 (고대) : Prof. 최의주 지도교수 (KIST) : Prof. 윤창노

2. Engineering novel binding proteins from nonimmunoglobulin domains

3. Engineering novel binding proteins from nonimmunoglobulin domains Therapeutic Antibodies on Market (2006)

4. Engineering novel binding proteins from nonimmunoglobulin domains Scaffolds used for generating protein binders with prescribed specificity

5. Engineering novel binding proteins from nonimmunoglobulin domains Scaffolds used for generating protein binders with prescribed specificity

6. Engineering novel binding proteins from nonimmunoglobulin domains Lipocalins in drug discovery: From natural ligand-binding proteins to ‘anticalins’

7. Engineering novel binding proteins from nonimmunoglobulin domains Lipocalins in drug discovery: From natural ligand-binding proteins to ‘anticalins’

8. Engineering novel binding proteins from nonimmunoglobulin domains Affibody binding proteins developed from a small three-helix bundle scaffold

9. Engineering novel binding proteins from nonimmunoglobulin domains Affibody binding proteins developed from a small three-helix bundle scaffold

10. Engineering novel binding proteins from nonimmunoglobulin domains Adnectins™ are a novel class of targeted biologics derived from human fibronectin

11. Engineering novel binding proteins from nonimmunoglobulin domains Comparison between camel Ig and IgG

12. Engineering novel binding proteins from nonimmunoglobulin domains Avimers : Human A-domain in cell surface receptors

13. Engineering novel binding proteins from nonimmunoglobulin domains Binding-site engineering strategies used with different alternative scaffolds

14. Engineering novel binding proteins from nonimmunoglobulin domains • Conclusion • IgGmolecules are comparatively difficult and expensive to manufacture. • Ideally, an alternative to antibodies should improve on all of limitations of IgG. • Several scaffolds unrelated to IgG have now been subjected to important proof-of-principle experiments. • The future application potential in research, diagnostics and therapy is readily apparent, and some of these applications have already been demonstrated successfully. • For therapeutic applications, however, the potential of alternative binding proteins has yet to be proven, and the scaffolds may be confronted with issues such as immunogenicity or lack of effector functions. • Nevertheless, several alternative binding proteins are currently in preclinical studies. • And the lack of effector functions may be compensated for by superior functionality or overcome by novel effector-fusion proteins.

15. Engineering novel binding proteins from nonimmunoglobulin domains Mergers and Acquisitions in the Biologics Sector

16. Engineering novel binding proteins from nonimmunoglobulin domains Partnering/Licensing deals in Biologics Discovery

17. Engineering novel binding proteins from nonimmunoglobulin domains • Summary • Maybe non-IgG folds can overcome limitation of IgG • Some of non-IgG folds will become Next generation antibodies • Big Pharma acquired IP covering Next generation antibodies discovery and manufacture • IF We Do Not Have Any IP of Next generation antibodies, The only thing We can Develop Biosimilar • Careful Investigation of your Proteins will unveil novel folds that could potentially utilize as antibody-like

18. Thank you